German firm Scil Technology established an independent unit, formycon, to provide services for protein drug formulation development, non-GMP and GMP drug product manufacturing and process development, quality control, and analytics. Formycon offers liquid and freeze-dried formulation expertise, in addition to liposomal and specialty formulations for topical and local administration.
“Scil Technology has established a unique expertise working on protein formulation and analytics for clients over the past decade,” comments Christian Nafe, Scil CEO. “Therefore it is a logical step to establish formycon as a dedicated service unit for external customers and partners.”
Scil is focused on the development of protein-based biotherapeutics for functional tissue regeneration in orthopedics and maxillofacial surgery. Lead Phase III-stage candidate MDO5 comprises a synthetic bone augmentation material coated with rhGDF-5, for use in dental implantology and the regeneration of tissue in periodontal disease. Preclinical-stage programs include the ST03, ST04, and ST05 programs, based on the cartilage growth factor, rhCD-RAP, which are focused on the repair of injury-damaged cartilage or age-related degenerative cartilage lesions.